Immunic

Immunic announces publication of extended data from phase 2 EMPhASIS Trial of vidofludimus calcium in relapsing-remitting multiple sclerosis in the peer-reviewed journal, Neurology Neuroimmunology & Neuroinflammation 

– 30 mg and 45 mg Daily Doses of Vidofludimus Calcium Suppressed Development of Gadolinium-Enhancing Lesions by 78% and 74% Compared to Pooled Placebo at 24 Weeks – – Improvements in Serum Neurofilament Light Chain Consistent with Recently Announced Interim Phase 2 CALLIPER Data in Progressive Multiple Sclerosis – – Twin Phase 3 ENSURE Trials...

Immunic, Inc. Added to NASDAQ Biotechnology Index

NEW YORK, Dec. 14, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December...
1200 Avenue of the Americas Suite 200 New York, NY 10036

+1 332 2559811